Once lauded for its clinical success, Roche casts off cardio program inclacumab for a mere $2M to Global Blood Therapeutics

Five years ago, Roche touted a clinical success for one of its mid-stage cardio programs, reporting the investigational med showed promise in reducing heart damage. Promising, they said, but apparently not promising enough.